Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Genmab

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Employees: 2.2K

Market Cap: $17.7B

Website: http://www.genmab.com

Clinical Trials

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Phase 1

Recruiting

Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Richter's Syndrome
Treatment-naïve High Risk Chronic Lymphocytic Leukemia

Interventions: Biological: Epcoritamab
Drug: Venetoclax
Drug: Lenalidomide
Drug: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
Drug: Pirtobrutinib

First Posted Date: 2020-11-10

Last Posted Date: 2025-06-03

Lead Sponsor: Genmab

Target Recruit Count: 424

Registration Number: NCT04623541

Locations: 🇺🇸
O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of California Davis Medical Center Sacramento, California, California, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 84 locations

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Phase 1

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma
Primary Mediastinal Large B Cell Lymphoma
High-grade B-cell Lymphoma
Follicular Lymphoma
Small Lymphocytic Lymphoma
Marginal Zone Lymphoma

Interventions: Biological: Epcoritamab (monotherapy)
Biological: Epcoritamab
Biological: Epcoritamab (maintenance)
Drug: Rituximab and lenalidomide
Drug: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Drug: Gemcitabine and oxaliplatin

First Posted Date: 2020-09-09

Last Posted Date: 2025-06-03

Lead Sponsor: Genmab

Target Recruit Count: 78

Registration Number: NCT04542824

Locations: 🇯🇵
Aichi Cancer Center Hospital, Aichi, Japan
🇯🇵
NHO Nagoya Medical Center, Aichi, Japan
🇯🇵
National Cancer Center Hospital East, Chiba, Japan

and more 11 locations

A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors

Phase 1

Terminated

Conditions: Prostate Cancer
Triple Negative Breast Cancer (TNBC)
Uterine Cancer
Squamous Cell Carcinoma of Head and Neck (SCCHN)
Non-small Cell Lung Cancer (NSCLC)
Bladder Cancer
Esophageal Cancer
Locally Advanced or Metastatic Solid Tumor(s)

Interventions: Biological: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.

First Posted Date: 2020-06-11

Last Posted Date: 2023-07-25

Lead Sponsor: Genmab

Target Recruit Count: 48

Registration Number: NCT04424641

Locations: 🇺🇸
Tennesse Oncology, PLLC - Nashville, Nashville, Tennessee, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇩🇰
Rigshospitalet (Copenhagen University Hospital), Copenhagen, Denmark

and more 3 locations

First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

Phase 1

Terminated

Conditions: Follicular Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Primary Mediastinal Large B-cell Lymphoma
Chronic Lymphocytic Leukemia
Diffuse Large B-cell Lymphoma
Small Lymphocytic Lymphoma
High-grade B-cell Lymphoma

Interventions: Biological: GEN3009
Biological: Epcoritamab

First Posted Date: 2020-04-24

Last Posted Date: 2024-10-24

Lead Sponsor: Genmab

Target Recruit Count: 46

Registration Number: NCT04358458

Locations: 🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 14 locations

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1

Active, not recruiting

Conditions: Malignant Solid Tumor
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions: Biological: GEN1042
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-FU
Drug: Gemcitabine
Drug: Nab paclitaxel
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2019-09-10

Last Posted Date: 2025-06-03

Lead Sponsor: Genmab

Target Recruit Count: 1287

Registration Number: NCT04083599

Locations: 🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸
Cancer & Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸
Moores Cancer Center at the UC San Diego Health, San Diego, California, United States

and more 72 locations

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma
Solid Tumors
Squamous Cell Carcinoma of the Head and Neck
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Cervical Cancer
Endometrial Carcinoma

Interventions: Biological: Acasunlimab
Biological: Acasunlimab in combination with docetaxel (in a single expansion cohort)
Biological: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Biological: Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)

First Posted Date: 2019-04-17

Last Posted Date: 2025-06-05

Lead Sponsor: Genmab

Target Recruit Count: 429

Registration Number: NCT03917381

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Yale University Cancer Center, New Haven, Connecticut, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 52 locations

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: tisotumab vedotin

First Posted Date: 2019-04-12

Last Posted Date: 2022-06-23

Lead Sponsor: Genmab

Target Recruit Count: 23

Registration Number: NCT03913741

Locations: 🇯🇵
National Cancer Center Hosptial East, Kashiwa-shi, Chiba-Ken, Japan
🇯🇵
NHO Shikoku Cancer Center, Matsuyama-Shi, Ehime-Ken, Japan
🇯🇵
NHO Hokkaido Cancer Center, Sapporo-shi, Hokkaido, Japan

and more 5 locations

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Marginal Zone Lymphoma (MZL)
Indolent B-cell Non-Hodgkin Lymphoma (iNHL)
Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
DLBCL
High-grade B-cell Lymphoma (HGBCL)
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
FL
MCL
Small Lymphocytic Lymphoma (SLL)

Interventions: Biological: Epcoritamab

First Posted Date: 2018-08-10

Last Posted Date: 2025-06-13

Lead Sponsor: Genmab

Target Recruit Count: 666

Registration Number: NCT03625037

Locations: 🇺🇸
Arizona Mayo Clinic, Phoenix, Arizona, United States
🇺🇸
University of California at San Francisco, San Francisco, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 82 locations

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

Phase 1

Terminated

Conditions: Gastric Cancer
Urothelial Cancer
Colorectal Cancer
Non-small Cell Lung Cancer
Renal Cell Carcinoma
Pancreatic Cancer
Triple Negative Breast Cancer

Interventions: Biological: GEN1029 (HexaBody®-DR5/DR5)

First Posted Date: 2018-07-03

Last Posted Date: 2023-08-01

Lead Sponsor: Genmab

Target Recruit Count: 48

Registration Number: NCT03576131

Locations: 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
UT M.D Anderson Cancer Center, Houston, Texas, United States
🇪🇸
Hospital Univeritario Vall d'Hebron, Barcelona, Spain

and more 3 locations

Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors

Phase 1

Completed

Conditions: Cervical Cancer
Endometrial Cancer
Thyroid Cancer
Melanoma
Sarcoma
Ovarian Cancer
Non Small Cell Lung Cancer (NSCLC)
Solid Tumors

Interventions: Biological: Enapotamab vedotin (HuMax-AXL-ADC)

First Posted Date: 2016-12-09

Last Posted Date: 2023-08-01

Lead Sponsor: Genmab

Target Recruit Count: 306

Registration Number: NCT02988817

Locations: 🇺🇸
Mayo Clinic - Phoenix, Phoenix, Arizona, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Yale University, Smilow Cancer Center at Yale New Haven Hospital, New Haven, Connecticut, United States

and more 38 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy